Aurinia Pharmaceuticals (AUPH) Enterprise Value (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Enterprise Value data on file, last reported at -$378.8 million in Q1 2026.

• Quarterly Enterprise Value fell 21.06% year-over-year to -$378.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$378.8 million (down 21.06% YoY) and the FY2025 annual result came in at -$398.0 million, down 11.02% from the prior year.
• Enterprise Value grew to -$378.8 million in Q1 2026, from -$398.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$312.9 million in Q1 2025 to a low of -$418.7 million in Q1 2022.
• A 5-year average of -$358.3 million and a median of -$351.8 million in 2025 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 16.45% in 2022, down 31.51% in 2022.
• Tracing AUPH's Enterprise Value over 5 years: stood at -$389.4 million in 2022, then rose by 9.99% to -$350.5 million in 2023, then fell by 2.28% to -$358.5 million in 2024, then dropped by 11.02% to -$398.0 million in 2025, then increased by 4.83% to -$378.8 million in 2026.
• The last three Enterprise Value figures came in at -$378.8 million (Q1 2026), -$398.0 million (Q4 2025), and -$351.8 million (Q3 2025), per Business Quant data.